Paper40468398
New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine.
Tian X and 9 others. Eur J Med Res, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine. Papers, record 40468398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40468398
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Precision Medicine | Major topic |
| Drug Development | Major topic |
| Hypoglycemic Agents | Major topic |
| Humans | |
| Gastrointestinal Microbiome | |
| Molecular Targeted Therapy | |
| Animals |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BJZYYB-2023-28 | Fundamental Research Funds for the China Academy of Chinese Medical Sciences | PubMed |
Source PubMed
References76
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39037913 | Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity. | Elife | 2024 | https://conductscience.org/library/papers/39037913 | PubMed |
| 2 | 15487979 | Psychological barriers. | Eur J Endocrinol | 2004 | https://conductscience.org/library/papers/15487979 | PubMed |
| 3 | 33463546 | Pharmacological treatment of hyperglycemia in type 2 diabetes. | J Clin Invest | 2021 | https://conductscience.org/library/papers/33463546 | PubMed |
| 4 | 30760847 | Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. | Nat Rev Endocrinol | 2019 | https://conductscience.org/library/papers/30760847 | PubMed |
| 5 | 32872570 | Pathophysiology of Type 2 Diabetes Mellitus. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32872570 | PubMed |
| 6 | 39059739 | Proteomics profiling and association with cardiorenal complications in type 2 diabetes subtypes in Asian population. | Diabetes Res Clin Pract | 2024 | https://conductscience.org/library/papers/39059739 | PubMed |
| 7 | 30672723 | In Vivo Silencing of MicroRNA-132 Reduces Blood Glucose and Improves Insulin Secretion. | Nucleic Acid Ther | 2019 | https://conductscience.org/library/papers/30672723 | PubMed |
| 8 | 31623194 | Glucose-Sensing Transcription Factor MondoA/ChREBP as Targets for Type 2 Diabetes: Opportunities and Challenges. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31623194 | PubMed |
| 9 | 34579087 | Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review. | Nutrients | 2021 | https://conductscience.org/library/papers/34579087 | PubMed |
| 10 | 37033254 | Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37033254 | PubMed |
| 11 | 33125843 | Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes. | J Med Chem | 2020 | https://conductscience.org/library/papers/33125843 | PubMed |
| 12 | 38095657 | Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. | Diabetologia | 2024 | https://conductscience.org/library/papers/38095657 | PubMed |
| 13 | 35982037 | Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. | Nat Commun | 2022 | https://conductscience.org/library/papers/35982037 | PubMed |
| 14 | 36342518 | Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes. | Diabetes | 2023 | https://conductscience.org/library/papers/36342518 | PubMed |
| 15 | 31424428 | β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. | J Clin Invest | 2019 | https://conductscience.org/library/papers/31424428 | PubMed |
| 16 | 37543292 | MicroRNA biomarkers target genes and pathways associated with type 2 diabetes. | Diabetes Res Clin Pract | 2023 | https://conductscience.org/library/papers/37543292 | PubMed |
| 17 | 35484823 | A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes. | Br J Pharmacol | 2022 | https://conductscience.org/library/papers/35484823 | PubMed |
| 18 | 36332637 | Type 2 diabetes. | Lancet | 2022 | https://conductscience.org/library/papers/36332637 | PubMed |
| 19 | 32556613 | Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Diabetologia | 2020 | https://conductscience.org/library/papers/32556613 | PubMed |
| 20 | 38891870 | MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38891870 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958439 | Inflammatory networks between adipose tissue, liver and pancreatic islets in type 2 diabetes. | Hum Genomics | 2026 | https://conductscience.org/library/papers/42958439 | PubMed |
| 42703356 | Association Between the Triglyceride-Glucose Index and Clinical Outcomes Modified by Diabetes Duration in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus. | Diabetes Metab Syndr Obes | 2026 | https://conductscience.org/library/papers/42703356 | PubMed |
| 41752213 | Photobiomodulation and Low-Level Laser Therapy as Complementary Strategies in Diabetes Treatment. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41752213 | PubMed |
| 41599783 | Emerging Breakthroughs in Nano-Ginseng Innovations and Their Therapeutic Implications in Type 2 Diabetes. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41599783 | PubMed |
| 41517974 | PGC-1α Transcriptionally Regulated by ChREBP Mitigates Neuropathic Pain Through Promoting Microglial Fatty Acid Oxidation and Anti-Inflammatory Response. | CNS Neurosci Ther | 2026 | https://conductscience.org/library/papers/41517974 | PubMed |
| 40919563 | Research Progress of Mitochondrial Dynamics and Autophagy in Diabetic Complications: New Treatment Strategies. | Diabetes Metab Syndr Obes | 2025 | https://conductscience.org/library/papers/40919563 | PubMed |
| 40565232 | Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40565232 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| MLXIP | 22877 | PubTator's text mining | https://conductscience.org/library/genes/22877 | NCBI Gene |
| MLXIPL | 51085 | PubTator's text mining | https://conductscience.org/library/genes/51085 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40468398
GET https://conductscience.org/api/papers/v1/40468398/references?page=2